Skip to content

Impact of Subcutaneous Electric Lumbar Stimulation on Treatment of Refractory Chronic and Disabling Lumbago

Impact of Subcutaneous Electric Lumbar Stimulation on Treatment of Refractory Chronic and Disabling Lumbago

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02988830
Acronym
IMESCUT
Enrollment
19
Registered
2016-12-09
Start date
2016-11-29
Completion date
2022-01-27
Last updated
2022-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Subcutaneous stimulation

Brief summary

The aim of the study is to show that subcutaneous electric lumbar stimulation reduces pain in chronic lumbago after 12 months of treatment.

Interventions

DEVICESubcutaneous Electric Lumbar Stimulation

Sponsors

Hopital Foch
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients over 18 years old * Having given their non-opposition * Affiliated to a national insurance scheme or beneficiary * Suffering for more than a year from a chronic, invalidating lumbago that is refractory in several lines of treatments

Exclusion criteria

* patients with lumbago that can be surgically handled or which justified a medullary stimulation * having been operated for the rachis for less than 6 months; * which cannot for cognitive or cultural reasons contribute to the planned evaluations and to the management of the material (remote control); * for who the investigator can plan that they cannot be followed during one year from the date of the setting-up (non-observance, planned moving, etc.); * which present psychological, local or general contraindications to the setting-up of a neurostimulation device (Impossibility to stop anticoagulants or aggregation inhibitors, disturb of the hemostasis, cutaneous infection change on the site of setting-up) * MRI planned within the next year * pregnant or breast-feeding women.

Design outcomes

Primary

MeasureTime frame
Average pain per day on visual analogical scale12 months

Secondary

MeasureTime frameDescription
Average pain per day on visual analogical scale15 days
OSWESTRY DISABILITY INDEX12 months
36-Item Short Form Health Survey score (SF 36)12 months
DALLAS self-questionnaire12 months
Douleur neuropathique 4 (DN4) score12 monthsDN4 is a French neuropathic pain scale
Questionnaire Hospital Anxiety and Depression scale (HAD)12 months
Pain Catastrophizing Scale (PCS)12 months
Coping strategies questionnaire (CSQ)12 months
Fear Avoidance Belief Questionnaire (FABQ)12 months
Tampa scale12 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026